Related Experiment Video
Updated: Nov 30, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
PARP inhibition in recurrent ovarian cancer
Kathleen N Moore1, Bhavana Pothuri2, Bradley Monk3
1Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Abstract:
With the introduction of PARP inhibitors into frontline chemotherapy, with or without bevacizumab, the hope exists that more women may be spared a recurrence of their ovarian cancer. Whether or not this proves to be true, the fact remains that many or most women with ovarian cancer will experience a recurrence requiring the use of additional active chemotherapy and targeted options. This manuscript summarizes the known data to date regarding the use of PARP inhibitors in the recurrent setting.
Related Concept Videos
Inhibition of Cdk Activity
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Restarting Stalled Replication Forks
Targeted Cancer Therapies
There are several types of targeted therapies against...
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

